Further subgroup analysis reveals that TLT treatment provides greater benefits for patients with tumor diameters greater than 7 cm, accompanied by PVTT, AFP levels greater than 400ng/ml, and being in the Child-Pugh A stage. The gene discussed is AFP; the disease is neoplasm.